Abstract
Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon upregulates TP in vivo, although the dose and schedule of interferon for optimal biomodulation of 5-FU is not known. In this study, TP activity was measured in peripheral blood lymphocytes (PBLs) from patients with advanced carcinoma receiving treatment with 5-FU and folinic acid. Cohorts of patients were treated with interferon alpha (IFNα), immediately prior to 5-FU/folinic acid, at doses of 3 MIU m–2, 9 MIU m–2 and 18 MIUm–2. IFNα was administered on day 0 cycle two, day –1 and day 0 cycle three and day –2, day –1 and day 0 cycle four. A fourth cohort was treated with IFNα 9 MIU m–2 three times per week from cycle 2 onwards. Twenty-one patients were entered into the study with 19 evaluable for response. Six patients (32%) had stable disease and 13 (68%) progressive disease. There were no grade-IV toxicities. TP activity was detected in PBLs from all patients with wide interpatient variability in constitutive TP activity prior to chemotherapy, and in response to IFNα. 5-FU/folinic acid alone did not induce TP activity but a single dose of IFNα led to upregulation of TP within 2 h of administration with a further increase by 24 h (signed rank test, P = 0.006). TP activity remained elevated for at least 13 days (signed rank test, P = 0.02). There were no significant differences in TP activity between schedules or with additional doses of IFNα. A single dose of IFNα as low as 3 MIU m–2 can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFNα for biomodulation of 5-FU. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Advanced Colorectal Cancer Meta-Analysis Project (A. C. C. M-A. P) (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903
Corfu-A Study Group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921–928
De Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B and Louvet C (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. European Journal of Cancer & Clinical Oncology 24: 1499–1503
Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC and Harris AL (1995) Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 176: 183–190
Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC and Harris AL (1996) The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73: 275–280
Giatromanolaki A, Koukourakis MI, Comley M, Kaklamanis L, Turley H, O’Byrne K, Harris AL and Gatter KC (1997) Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol 181: 196–199
Houghton JA, Morton CL, Adkins DA and Rahman A (1993) Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Cancer Res 53: 4243–4250
Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E and Fountzilas G (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14: 2682–2687
Makower D, Wadler S, Haynes H and Schwartz EL (1997) Interferon induces thymidine phosphorylase/platelet derived endothelial cell growth factor expression in vivo. Clinical Cancer Research 3: 923–929
Matthews JN, Altman DG, Campbell MJ and Royston P (1990) Analysis of serial measurements in medical research. BMJ 300: 230–235
Moghaddam A and Bicknell R (1992) Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31: 12141–12146
Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL and Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Nat Acad Sci USA 92: 998–1002
Moran RG and Scanlon KL (1991) Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618–4623
O’Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, Gatter KC, Bicknell R and Harris AL (1996) Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56: 4799–4804
Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ and Harris AL (1995) Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669–675
Ragnhammar P, Blomgren H, Edler D, Lundell G, Magnusson I and Sonnenfeld T (1995) Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma. Eur J Cancer 31A: 315–320
Schwartz EL, Baptiste N, O’Connor CJ, Wadler S and Otter BA (1994) Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 54: 1472–1478
Schwartz EL, Baptiste N, Wadler S and Makower D (1995) Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073–19077
Seymour MT, Johnson PW, Hall MR, Wrigley PF and Slevin ML 1994 a) Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. Br J Cancer 70: 719–723
Seymour MT, Patel N, Johnston A, Joel SP and Slevin ML 1994 b) Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. Br J Cancer 70: 724–728
Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, Perren TJ, McAdam WA, Harper PG, Neoptolemos JP, Nicholson M, Duffy AM, Stephens RJ, Stenning SP and Taylor I (1996) Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 14: 2280–2288
Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M and Ellis LM (1998) Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clinical Cancer Research 4: 429–434
Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S and Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A: 1227–1232
Wadler S, Goldman M, Lyver A and Wiernik PH 1990 a) Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 50: 2056–2059
Wadler S, Wersto R, Weinberg V, Thompson D and Schwartz EL 1990 b) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50: 5735–5739
Wadler S, Lembersky B, Atkins M, Kirkwood J and Petrelli N (1991) Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 9: 1806–1810
Wadler S, Horowitz R, Mao X and Schwartz EL (1996) Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol 38: 529–5235
Woolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacker L, Romond D, Colangelo L and Fisher B (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90: 1810–1816
Yoshikawa T, Suzuki K, Kobayashi O, Sairenji M, Motohashi H, Tsuburaya A, Nakamura Y, Shimizu A, Yanoma S and Noguchi Y (2000) Thymidine phosphorylase/platelet-derived endothelial cell growth factor is upregulated in advanced solid types of gastric cancer. Br J Cancer 79: 1145–1150
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Braybrooke, J., Propper, D., O’Byrne, K. et al. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer 83, 219–224 (2000). https://doi.org/10.1054/bjoc.2000.1230
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1230
Keywords
This article is cited by
-
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis
Journal of Gastroenterology (2009)
-
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents
British Journal of Cancer (2003)